Acute Effect of Propranolol and Isosorbide-5-mononitrate Administration on Renal Blood Flow in Cirrhotic Patients

Overview

Journal Gut

Specialty Gastroenterology

Date 1998 Apr 16

PMID 9536956

Citations 2

Authors

A J Stanley

I A Bouchier

P C Hayes

Affiliations

Soon will be listed here.

Abstract

Background: Propranolol and isosorbide-5-mononitrate (ISMN) are increasingly used in the prophylaxis of variceal haemorrhage in cirrhosis. However, recent studies have suggested that these drugs may compromise renal function, possibly by reducing renal blood flow.

Aims: To assess the acute effects of propranolol and ISMN on renal blood flow and other haemodynamic parameters in cirrhosis.

Patients And Methods: Twenty six cirrhotic patients were given either 80 mg propranolol, 20 mg ISMN, or a combination of the two drugs. Unilateral renal blood flow (RBF), azygos blood flow (AZBF), hepatic venous pressure gradient (HVPG), mean arterial pressure (MAP), and heart rate (HR) were recorded prior to and one hour after drug administration.

Results: Propranolol caused a reduction in HR (p < 0.005), AZBF (p < 0.01), and HVPG (p = 0.05), but no change in MAP or RBF (454.1 (77.3) versus 413.9 (60.3) ml/min). ISMN reduced MAP (p < 0.005) and HVPG (p < 0.01), but had no effect on HR, AZBF, or RBF (302.5 (49.4) versus 301.7 (58.8) ml/min). Combined treatment reduced MAP (p < 0.005), AZBF (p < 0.05), and HVPG (p = 0.002), but HR and RBF (419.2 (62.6) versus 415.1 (61.1) ml/min) remained unchanged.

Conclusions: Despite the anticipated changes in other haemodynamic parameters, acute propranolol and/or ISMN administration did not reduce RBF. These drugs do not seem to compromise RBF in cirrhosis.

Citing Articles

Association of non-selective β blockers with the development of renal dysfunction in liver cirrhosis: a systematic review and meta-analysis.

Xu X, Gao F, Wang T, Yang Z, Zhao Q, Qi X Ann Med. 2024; 56(1):2305935.

PMID: 38271554 PMC: 10812853. DOI: 10.1080/07853890.2024.2305935.

Hepatoprotective effects of the nitric oxide donor isosorbide-5-mononitrate alone and in combination with the natural hepatoprotectant, silymarin, on carbon tetrachloride-induced hepatic injury in rats.

Abdel Salam O, Sleem A, Shafee N Inflammopharmacology. 2010; 18(2):87-94.

PMID: 20069380 DOI: 10.1007/s10787-009-0027-7.

References

Garcia-Pagan J, Feu F, Bosch J, Rodes J . Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med. 1991; 114(10):869-73. DOI: 10.7326/0003-4819-114-10-869. View

Garcia-Pagan J, Feu F, Navasa M, Bru C, Ruiz Del Arbol L, Bosch J . Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension. J Hepatol. 1990; 11(2):189-95. DOI: 10.1016/0168-8278(90)90112-5. View

CONN H, Grace N, Bosch J, Groszmann R, Rodes J, Wright S . Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group. Hepatology. 1991; 13(5):902-12. View

Hayes P, Terrace D, Peaston I, Bouchier I, Redhead D, Brash H . Computerised system for the continuous measurement of azygos venous blood flow. Gut. 1992; 33(3):372-4. PMC: 1373831. DOI: 10.1136/gut.33.3.372. View

Henriksen J, Bendtsen F, Gerbes A, Christensen N, Ring-Larsen H, Sorensen T . Estimated central blood volume in cirrhosis: relationship to sympathetic nervous activity, beta-adrenergic blockade and atrial natriuretic factor. Hepatology. 1992; 16(5):1163-70. View

Ljubicic N, Bilic A, Plavsic V . Effect of propranolol on urinary prostaglandin E2 excretion and renal interlobar arterial blood flow after furosemide administration in patients with hepatic cirrhosis. Eur J Clin Pharmacol. 1992; 43(5):555-8. DOI: 10.1007/BF02285102. View

Angelico M, Carli L, Piat C, Gentile S, Rinaldi V, Bologna E . Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis. Gastroenterology. 1993; 104(5):1460-5. DOI: 10.1016/0016-5085(93)90356-h. View

Salmeron J, Ruiz Del Arbol L, Gines A, Garcia-Pagan J, Gines P, Feu F . Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. Hepatology. 1993; 17(5):800-6. View

Vorobioff J, Picabea E, Gamen M, Villavicencio R, Bordato J, Bessone F . Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients: long-term hemodynamic and renal effects. Hepatology. 1993; 18(3):477-84. View

10.

Henriksen J, Ring-Larsen H . Renal effects of drugs used in the treatment of portal hypertension. Hepatology. 1993; 18(3):688-95. View

11.

Bertoni G, Sassatelli R, Fornaciari G, Briglia R, Tansini P, Grisendi A . Oral isosorbide-5-mononitrate reduces the rebleeding rate during the course of injection sclerotherapy for esophageal varices. Scand J Gastroenterol. 1994; 29(4):363-70. DOI: 10.3109/00365529409094851. View

12.

Morillas R, Planas R, Cabre E, Galan A, Quer J, Feu F . Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects. Hepatology. 1994; 20(6):1502-8. DOI: 10.1002/hep.1840200620. View

13.

Bolognesi M, Sacerdoti D, Merkel C, Gatta A . Duplex Doppler sonographic evaluation of splanchnic and renal effects of single agent and combined therapy with nadolol and isosorbide-5-mononitrate in cirrhotic patients. J Ultrasound Med. 1994; 13(12):945-52. DOI: 10.7863/jum.1994.13.12.945. View

14.

DAmico G, Pagliaro L, Bosch J . The treatment of portal hypertension: a meta-analytic review. Hepatology. 1995; 22(1):332-54. DOI: 10.1002/hep.1840220145. View

15.

Merkel C, Gatta A, Donada C, Enzo E, Marin R, Amodio P . Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. GTIP Gruppo Triveneto per l'Ipertensione Portale. Hepatology. 1995; 22(3):808-13. DOI: 10.1002/hep.1840220318. View

16.

Salerno F, Borroni G, Lorenzano E, Solenghi D, Cazzaniga M, Bissoli F . Long-term administration of isosorbide-5-mononitrate does not impair renal function in cirrhotic patients. Hepatology. 1996; 23(5):1135-40. DOI: 10.1053/jhep.1996.v23.pm0008621145. View

17.

Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T . Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. J Hepatol. 1997; 26(2):312-24. DOI: 10.1016/s0168-8278(97)80047-5. View

18.

Hornych A, Brod J, Slechta V . The measurement of the renal venous outflow in man by the local thermodilution method. Nephron. 1971; 8(1):17-32. DOI: 10.1159/000179903. View

19.

Wilkinson S, Bernardi M, Smith I, Jowett T, Slater J, Williams R . Effect of beta adrenergic blocking drugs on the renin-aldosterone system, sodium excretion, and renal hemodynamics in cirrhosis with ascites. Gastroenterology. 1977; 73(4 Pt 1):659-63. View

20.

Wilkinson R . Beta-blockers and renal function. Drugs. 1982; 23(3):195-206. DOI: 10.2165/00003495-198223030-00002. View